Range of suitable people: CDEC discussed the uncertainty in the number of patients with reasonably severe to serious hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some people who will be labeled as acquiring delicate or moderate disease might have a serious bleeding phen… Read More